Dysregulation of GPCR signaling, particularly calcium signaling, has been implicated in different diseases, e.g. cancer and Alzheimer’s disease. Currently about 34% of all FDA approved drugs target GPCRs indicating their importance for drug discovery, and in vitro cellular GPCR assays are important tools to identify new drugs.
Our application note describes how to analyze fast changes in intracellular calcium levels upon GPCR stimulation and inhibition using a fluorescence imaging assay on the Opera Phenix® Plus high-content screening system.